
Sign up to save your podcasts
Or
Wen Wee Ma, MBBS, Enterprise Vice Chair for Research and Director of the Novel Cancer Therapeutics Center, joins the Cancer Advances Podcast to discuss a phase 1 trial of KB707 presented at ASCO 2025. This innovative therapy delivers IL-2 and IL-12 directly to the lungs through inhalation, aiming to minimize side effects and improve outcomes for patients with lung tumors. Dr. Ma shares early trial results and what they could mean for the future of cancer treatment.
5
2424 ratings
Wen Wee Ma, MBBS, Enterprise Vice Chair for Research and Director of the Novel Cancer Therapeutics Center, joins the Cancer Advances Podcast to discuss a phase 1 trial of KB707 presented at ASCO 2025. This innovative therapy delivers IL-2 and IL-12 directly to the lungs through inhalation, aiming to minimize side effects and improve outcomes for patients with lung tumors. Dr. Ma shares early trial results and what they could mean for the future of cancer treatment.
8,733 Listeners
500 Listeners
704 Listeners
58 Listeners
2,428 Listeners
3,338 Listeners
56,433 Listeners
90 Listeners
4,878 Listeners
3,528 Listeners
8,046 Listeners
515 Listeners
368 Listeners
252 Listeners
184 Listeners